Cellectar Biosciences (CLRB) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. NVDA
3. PCVX
4. PTC
5. ATH
6. CME
7. USO
8. AMD
9. EVTL
10. KLC

Go back to Cellectar Biosciences (CLRB) Misses Q1 EPS by 1c

Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

May 11, 2018 8:00 AM EDT

MADISON, Wis., May 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported recent corporate highlights and financial results for the three months ended March 31, 2018.

Recent Corporate Highlights

Received orphan drug designation and rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for CLR 131 to treat neuroblastoma. Received orphan drug designation from the FDA for CLR 131 to treat... More